DaVita Inc hits 52-week low amid market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
Should l Buy DVA?
Source: NASDAQ.COM
DaVita Inc's stock price fell by 3.21% during regular trading, hitting a 52-week low. This decline occurs in a mixed market environment, with the Nasdaq-100 up 0.11% and the S&P 500 down 0.31%.
The drop in DaVita's stock price is attributed to broad market weakness, as the overall market sentiment has shifted despite some gains in the Nasdaq-100. This indicates a potential sector rotation, where investors may be reallocating their investments away from healthcare stocks like DaVita.
Investors are closely monitoring the company's performance and market trends, as the healthcare sector faces challenges amid changing investor preferences. The recent price movement may prompt further analysis of DaVita's strategic positioning in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 136.50 USD with a low forecast of 130.00 USD and a high forecast of 143.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
0 Buy
3 Hold
1 Sell
Hold
Current: 149.220
Low
130.00
Averages
136.50
High
143.00
Current: 149.220
Low
130.00
Averages
136.50
High
143.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Berkshire Hathaway Stock Outperforms Amid Tech Sell-Off
- Cash Reserve Advantage: Berkshire Hathaway's cash reserves exceeding $350 billion have become a significant asset as technology stocks face sell-offs due to AI spending outpacing revenues, leading to a 5.6% increase in A shares and a 5.7% rise in B shares.
- DaVita Stock Surge: DaVita's stock soared nearly 29% this week after reporting Q4 earnings that exceeded analysts' expectations, which is positive for Berkshire, holding a 44% stake valued at $4.2 billion.
- Impact of Share Sale: Despite DaVita's stock surge, Berkshire sold almost 1.7 million shares at a pre-surge price of $120.56 each last Thursday, totaling nearly $200 million, which limits its stake in DaVita to below 45% as per their agreement.
- Borsheims Store Renovation: Berkshire's subsidiary Borsheims plans a major architectural transformation of its flagship Omaha jewelry store to enhance customer experience and solidify its status as a luxury destination, with renovations set to begin after May's annual meeting while remaining open during construction.
See More
Buffett Leaves Abel with a $320 Billion Portfolio Challenge
- Massive Portfolio: Upon stepping down at the end of 2025, Buffett left Berkshire Hathaway with a marketable equity portfolio valued at approximately $320 billion and $354 billion in cash reserves, presenting new CEO Abel with significant management challenges as investors await his strategic adjustments.
- First Stock Sale: Under Abel's leadership, Berkshire disclosed the sale of 1.7 million shares of DaVita (DVA), which, while executed under a pre-existing agreement, raised concerns among investors about potential reductions in holdings, thereby impacting market confidence.
- Strong DaVita Performance: DaVita's recent earnings report revealed a 10% revenue increase and a 52% surge in adjusted earnings per share (EPS), and despite ongoing concerns regarding flu season and GLP-1 drug impacts, management's optimistic forecast of 45% EPS growth for 2026 indicates a positive outlook.
- Potential Kraft Heinz Sale: Abel appears poised to sell Berkshire's stake in Kraft Heinz (KHC), despite Buffett's previous comments on the merger's shortcomings; Abel's disapproval of the company's split plan may present an opportunity for Berkshire to divest its shares.
See More
Warren Buffett Steps Down as CEO of Berkshire Hathaway
- Leadership Change: Warren Buffett's resignation as CEO of Berkshire Hathaway after over 65 years marks a significant turning point in the company's history, potentially impacting investor confidence and future strategic direction.
- Stock Sales Overview: Berkshire's recent stock sales totaled $12.5 billion, involving six stocks including Apple and Bank of America, indicating Buffett's cautious stance on high-valuation stocks, which may affect the company's short-term earnings performance.
- Investment Strategy Shift: In the third quarter, Berkshire allocated nearly $6.4 billion to stock purchases while adding $9.9 billion to short-term U.S. Treasury Bills, reflecting Buffett's concerns about market valuations and emphasis on liquidity, which could influence future investment decisions.
- Increased Cash Allocation: Currently, cash and Treasury Bills make up about one-third of Berkshire's total value, demonstrating Buffett's cautious approach to the current market environment, which may pose greater challenges for the company in finding viable investment opportunities.
See More
Buffett Sells Stocks for 12 Consecutive Quarters
- Selling Trend: Buffett has been a net seller of stocks for 12 consecutive quarters, with the latest round of sales totaling $12.5 billion, indicating his concerns about market valuations that could impact Berkshire Hathaway's portfolio performance.
- High-Yield Investments: Despite selling, Berkshire invested nearly $6.4 billion in equities during Q3, with $9.9 billion allocated to short-term U.S. Treasury Bills, reflecting a focus on liquidity and safety that may influence future investment strategies.
- Apple and Bank of America Reductions: Buffett has been trimming his stakes in Apple and Bank of America due to their high valuations, as Apple's stock has surged in recent years and Bank of America's price approached twice its tangible book value, prompting a reassessment of their investment worth.
- Cash Position Maintenance: Berkshire now holds cash and Treasury Bills amounting to one-third of its total value, demonstrating Buffett's cautious stance on the current market, which may affect his future investment decisions and market engagement.
See More
DaVita (DVA) Q2 2025 Earnings Call Transcript
See More
DaVita (DVA) Q1 2025 Earnings Call Transcript
See More
Berkshire Hathaway Stock Outperforms Amid Tech Sell-Off
- Cash Reserve Advantage: Berkshire Hathaway's cash reserves exceeding $350 billion have become a significant asset as technology stocks face sell-offs due to AI spending outpacing revenues, leading to a 5.6% increase in A shares and a 5.7% rise in B shares.
- DaVita Stock Surge: DaVita's stock soared nearly 29% this week after reporting Q4 earnings that exceeded analysts' expectations, which is positive for Berkshire, holding a 44% stake valued at $4.2 billion.
- Impact of Share Sale: Despite DaVita's stock surge, Berkshire sold almost 1.7 million shares at a pre-surge price of $120.56 each last Thursday, totaling nearly $200 million, which limits its stake in DaVita to below 45% as per their agreement.
- Borsheims Store Renovation: Berkshire's subsidiary Borsheims plans a major architectural transformation of its flagship Omaha jewelry store to enhance customer experience and solidify its status as a luxury destination, with renovations set to begin after May's annual meeting while remaining open during construction.
See More
Buffett Leaves Abel with a $320 Billion Portfolio Challenge
- Massive Portfolio: Upon stepping down at the end of 2025, Buffett left Berkshire Hathaway with a marketable equity portfolio valued at approximately $320 billion and $354 billion in cash reserves, presenting new CEO Abel with significant management challenges as investors await his strategic adjustments.
- First Stock Sale: Under Abel's leadership, Berkshire disclosed the sale of 1.7 million shares of DaVita (DVA), which, while executed under a pre-existing agreement, raised concerns among investors about potential reductions in holdings, thereby impacting market confidence.
- Strong DaVita Performance: DaVita's recent earnings report revealed a 10% revenue increase and a 52% surge in adjusted earnings per share (EPS), and despite ongoing concerns regarding flu season and GLP-1 drug impacts, management's optimistic forecast of 45% EPS growth for 2026 indicates a positive outlook.
- Potential Kraft Heinz Sale: Abel appears poised to sell Berkshire's stake in Kraft Heinz (KHC), despite Buffett's previous comments on the merger's shortcomings; Abel's disapproval of the company's split plan may present an opportunity for Berkshire to divest its shares.
See More
Warren Buffett Steps Down as CEO of Berkshire Hathaway
- Leadership Change: Warren Buffett's resignation as CEO of Berkshire Hathaway after over 65 years marks a significant turning point in the company's history, potentially impacting investor confidence and future strategic direction.
- Stock Sales Overview: Berkshire's recent stock sales totaled $12.5 billion, involving six stocks including Apple and Bank of America, indicating Buffett's cautious stance on high-valuation stocks, which may affect the company's short-term earnings performance.
- Investment Strategy Shift: In the third quarter, Berkshire allocated nearly $6.4 billion to stock purchases while adding $9.9 billion to short-term U.S. Treasury Bills, reflecting Buffett's concerns about market valuations and emphasis on liquidity, which could influence future investment decisions.
- Increased Cash Allocation: Currently, cash and Treasury Bills make up about one-third of Berkshire's total value, demonstrating Buffett's cautious approach to the current market environment, which may pose greater challenges for the company in finding viable investment opportunities.
See More
Buffett Sells Stocks for 12 Consecutive Quarters
- Selling Trend: Buffett has been a net seller of stocks for 12 consecutive quarters, with the latest round of sales totaling $12.5 billion, indicating his concerns about market valuations that could impact Berkshire Hathaway's portfolio performance.
- High-Yield Investments: Despite selling, Berkshire invested nearly $6.4 billion in equities during Q3, with $9.9 billion allocated to short-term U.S. Treasury Bills, reflecting a focus on liquidity and safety that may influence future investment strategies.
- Apple and Bank of America Reductions: Buffett has been trimming his stakes in Apple and Bank of America due to their high valuations, as Apple's stock has surged in recent years and Bank of America's price approached twice its tangible book value, prompting a reassessment of their investment worth.
- Cash Position Maintenance: Berkshire now holds cash and Treasury Bills amounting to one-third of its total value, demonstrating Buffett's cautious stance on the current market, which may affect his future investment decisions and market engagement.
See More
DaVita (DVA) Q2 2025 Earnings Call Transcript
See More
DaVita (DVA) Q1 2025 Earnings Call Transcript
See More
